ReviewMolecular cancer2022
Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer.
Review in Molecular cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 2 syntheses or guidelines pooled it, 207 citations in OpenAlex.
- A systematic review and meta-analysis of circulating serum and plasma microRNAs in TB diagnosis.BMC infectious diseases · 2024Pooled it
- The clinical implications of circulating microRNAs as potential biomarkers in screening oral squamous cell carcinoma.Frontiers in oncology · 2022Pooled it
- Role of liquid biopsy in the multimodal assessment and treatment of esophageal cancer: a surgical perspective.Updates in surgery · 2026Article
- Urinary exosomal microRNAs in Kawasaki disease and their changes after treatment.Pediatric research · 2026Article
- Integrative analysis of TCGA data identifies hsa-miR-200a as a breast cancer-associated microRNA biomarker with exploratory serum validation.Genes & genomics · 2026Article
- SERS detection of osteoarthritis-linked microRNA-204 via a DNAzyme-catalyzed self-amplifying circuit.Journal of pharmaceutical analysis · 2026Article
- The role of liquid biopsy in the molecular characterization of HPV-related cancers.Folia microbiologica · 2026Review
- Circulating EV-microRNAs are dynamic biomarkers of resistance to therapeutic immunomodulation in metastatic melanoma.Communications medicine · 2026Article
- Exosomal MicroRNAs as Drivers of Desmoplasia and Treatment Resistance in Breast Cancer: Mechanisms, Biomarker Potential, and Therapeutic Opportunities.Biomolecules · 2026Review
- Review
- Identification of plasma exosome circRNA as potential novel biomarkers for DLBCL and circrna-miRNA-mRNA network analysis.Clinical and experimental medicine · 2026Article
- The role of BLZF1 in lung adenocarcinoma and its value as a diagnostic and prognostic biomarker.Scientific reports · 2026Article
- An exosome-based liquid biopsy to predict molecular residual disease for the identification of high-risk patients with stage II-III colorectal cancer: the CLEAR study.Molecular cancer · 2026Observational
- Visualizing extracellular vesicles in cancer: from biogenesis to theranostic applications.Journal of nanobiotechnology · 2026Review
- Roles of Exosome-Derived Noncoding RNA in Fibrosis.Molecules and cells · 2026Review
- Genetic landscape of cancer: mechanisms, key genes, and therapeutic implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Experimental Validation of miR-4443, miR-572, and miR-150-5p in Serum and Tissue of Breast Cancer Patients as a Potential Diagnostic Biomarker: A Study Based on Bioinformatics Prediction.Biochemical genetics · 2026Article
- Anionic Liposomes as Optimal Membrane Fusion Carriers Enabling in Situ Multiplexed Detection of Extracellular Vesicle MicroRNAs.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Investigating Sex-Linked miRNAs for Potential Osteoarthritis Therapy Biomarkers.International journal of molecular sciences · 2026Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDetecting cancer at an early stage before clinical manifestation could be an effective strategy to decrease cancer mortality. Thus, identifying liquid biopsy biomarkers with high efficacy could be a promising approach for non-invasive diagnosis of cancer. MAIN TEXT: Liquid biopsies are increasingly used as a supplement to biopsy, as it enables disease progression to be detected months before clinical and radiographic confirmation. Many bodily fluids contain exosomal microRNAs (miRNAs) which could provide a new class of biomarkers for early and minimally invasive cancer diagnosis due to the stability of miRNAs in exosomes. In this review, we mainly focused on the exosomal miRNAs (liquid biopsy) as biomarkers in the diagnosis and prognosis of various cancers.
conclusionExosomal miRNAs can be used as diagnostic and prognosis biomarkers that provide unique insights and a more dynamic perspective of the progression and therapeutic responses in various malignancies. Therefore, the development of novel and more sensitive technologies that exploit exosomal miRNAs should be a priority for cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.